Breaking News Instant updates and real-time market news.

2022-07-06 08:32:54 HTGM HTG Molecular $1.14 / +0.065 (+6.05%) 08:32 07/06/22 07/06 08:32 07/06/22 08:32	HTG Molecular releases whitepaper for transcriptome-informed approach HTG Molecular Diagnostics has released a second white paper, further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology. A cornerstone of HTG's Therapeutics business, the HTG Transcriptome Panel was launched with commercial availability in August of 2021. The HTP was designed to enable the assessment of approximately 20,000 mRNA targets using HTG's EdgeSeq technology, a targeted RNA sequencing technology that couples a nuclease protection assay with next-generation sequencing for rapid and accurate RNA quantification. HTG EdgeSeq's many advantages include a 96-well plate format, low sample input requirement, no RNA extraction, and rapid assay and analysis time. We believe these benefits make it an attractive technology for applying transcriptomic profiling to drug discovery. The White Paper describes the use of HTG's transcriptome-informed drug design and discovery platform in early-stage design, selection and characterization of small-molecule candidates for an initial therapeutic target. The results of the studies summarized in the White Paper revealed several indication-specific effects as well as potential undesirable effects of the initial therapeutic target through analysis of the transcriptomic profiles from compound-treated human cell line test systems.

2022-07-06 08:32:54

HTGM

HTG Molecular

$1.14 / +0.065 (+6.05%)

08:32

07/06/22

07/06

08:32

07/06/22

08:32

HTG Molecular releases whitepaper for transcriptome-informed approach

HTG Molecular Diagnostics has released a second white paper, further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology. A cornerstone of HTG's Therapeutics business, the HTG Transcriptome Panel was launched with commercial availability in August of 2021. The HTP was designed to enable the assessment of approximately 20,000 mRNA targets using HTG's EdgeSeq technology, a targeted RNA sequencing technology that couples a nuclease protection assay with next-generation sequencing for rapid and accurate RNA quantification. HTG EdgeSeq's many advantages include a 96-well plate format, low sample input requirement, no RNA extraction, and rapid assay and analysis time. We believe these benefits make it an attractive technology for applying transcriptomic profiling to drug discovery. The White Paper describes the use of HTG's transcriptome-informed drug design and discovery platform in early-stage design, selection and characterization of small-molecule candidates for an initial therapeutic target. The results of the studies summarized in the White Paper revealed several indication-specific effects as well as potential undesirable effects of the initial therapeutic target through analysis of the transcriptomic profiles from compound-treated human cell line test systems.

OTHER BREAKING NEWS FROM THE FLY

Downgrade	K+S AG downgraded to Sector Perform from Outperform at Scotiabank » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 KPLUY K+S AG $10.87 / +0.28 (+2.64%) , NTR Nutrien $90.51 / +0.045 (+0.05%) , CF CF Industries $101.91 / +0.01 (+0.01%) Scotiabank analyst Ben… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/08/22 Nutrien name Ken Seitz as President and CEO 07/20/22 Nutrien to acquire Casa do Adubo, terms undisclosed 06/09/22 Nutrien announces plans to increase fertilizer production capacity 05/18/22 Denbury, Nutrien enter agreement for transportation and storage of CO2 CF CF Industries $101.91 / +0.01 (+0.01%) 07/18/22 CF Industries 'disappointed' by ITC injury determination on UAN imports 06/08/22 CF Industries to shut one of its U.K. manufacturing facilities 06/06/22 CF Industries exec Hoker sells 6,684 common shares 05/03/22 CF Industries, Mitsui announce plans for ammonia production facility in U.S. KPLUY NTR CF KPLUY K+S AG $10.87 / +0.28 (+2.64%) 07/18/22 Morgan Stanley K+S AG price target lowered to EUR 24 from EUR 26.50 at Morgan Stanley 05/12/22 Morgan Stanley K+S AG price target raised to EUR 26.50 from EUR 20.50 at Morgan Stanley 05/12/22 Scotiabank K+S AG price target raised to EUR 40 from EUR 38 at Scotiabank 04/20/22 DZ Bank K+S AG downgraded to Hold from Buy at DZ Bank NTR Nutrien $90.51 / +0.045 (+0.05%) 08/10/22 Barclays Nutrien price target lowered to $105 from $126 at Barclays 08/09/22 Scotiabank Nutrien upgraded to Outperform from Sector Perform at Scotiabank 07/18/22 RBC Capital ITC ruling against U.S. UAN tariffs negative for CF Industries, says RBC Capital 07/14/22 Credit Suisse Nutrien initiated with an Underperform at Credit Suisse CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Barclays CF Industries upgraded to Overweight from Equal Weight at Barclays 08/03/22 Scotiabank CF Industries upgraded to Outperform from Sector Perform at Scotiabank 08/03/22 Citi CF Industries upgraded to Buy on tighter ag conditions at Citi 08/03/22 Citi CF Industries upgraded to Buy from Neutral at Citi NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/03/22 Nutrien cuts FY22 EPS view to $15.80-$17.80 from $16.20-$18.70 08/03/22 Nutrien reports Q2 EPS $6.51, consensus $5.76 05/02/22 Nutrien raises FY22 EPS view to $16.20-$18.70 from $10.20-$11.80 05/02/22 Nutrien reports Q1 EPS $2.70, consensus $2.72 CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries reports Q2 EPS $5.58, consensus $6.12 08/01/22 Notable companies reporting after market close 05/04/22 CF Industries reports Q1 EPS $4.21, consensus $4.35 02/15/22 CF Industries reports Q4 EPS $3.27, consensus $3.51 CF CF CF Industries $101.91 / +0.01 (+0.01%) 03/22/22 Agriculture stocks see increased demand amid Ukraine turmoil, Bloomberg says NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/28/22 What You Missed On Wall Street This Morning 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/03/22 Fly Intel: Pre-market Movers CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Nutrien - NTR NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 06/23/22 Nutrien put volume heavy and directionally bearish 06/10/22 Nutrien put volume heavy and directionally bearish 06/03/22 Nutrien put volume heavy and directionally bearish 05/12/22 Nutrien call volume above normal and directionally bullish CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries options imply 5.1% move in share price post-earnings 07/18/22 CF Industries put volume heavy and directionally bearish 07/15/22 Unusually active option classes on open July 15th 07/14/22 CF Industries put volume heavy and directionally bearish
Hot Stocks	SciSparc issued Israeli patent for tech treating CNS disorders » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 SPRC SciSparc $1.19 / -0.025 (-2.06%) SciSparc announced it has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News SPRC SciSparc $1.19 / -0.025 (-2.06%) 08/08/22 SciSparc announces Israeli Ministry of Health approval for ASD trial 08/01/22 SciSparc signs clinical trial agreement with Yale University 07/08/22 SciSparc to expand clinical operation to include U.S. site towards SCI-110 trial 07/07/22 SciSparc's JV MitoCareX Bio launches new laboratory facility in Israel
Recommendations	AppLovin price target lowered to $70 from $80 at DA Davidson » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 APP AppLovin $34.46 / -6.01 (-14.85%) , U Unity $54.30 / -1.21 (-2.18%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin drops 10% to $36.55 after reporting Q2 losses 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Unity wins three-year contract from CACI 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 BTIG AppLovin price target lowered to $53 from $60 at BTIG 08/11/22 Truist AppLovin price target lowered to $65 from $77 at Truist 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi 08/10/22 Oppenheimer Unity price target raised to $60 from $54 at Oppenheimer 08/10/22 Benchmark Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin sees FY22 revenue $2.84B-$3.14B, consensus $3.29B 08/10/22 AppLovin reports Q2 EPS (6c), consensus 18c 08/10/22 Notable companies reporting after market close 08/09/22 AppLovin lowers FY22 revenue view to $2.84B-$3.14B from $3.14B-$3.44B U Unity $54.30 / -1.21 (-2.18%) 08/09/22 Unity sees FY22 revenue $1.3B-$1.35B, consensus $1.36B 08/09/22 Unity sees Q3 revenue $315M-$335M, consensus $346.87M 08/09/22 Unity reports Q2 EPS (18c), consensus (21c) 08/09/22 Notable companies reporting after market close 03 Dec APP U APP AppLovin $34.46 / -6.01 (-14.85%) 06/30/22 AppLovin cuts 12% of workforce, AdExchanger reports U Unity $54.30 / -1.21 (-2.18%) 08/02/22 Unity in talks to spin off China unit, Reuters reports 06/29/22 Unity lays off hundreds of workers, Kotaku reports APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/10/22 Fly Intel: After-Hours Movers 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter U Unity $54.30 / -1.21 (-2.18%) 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter 08/09/22 Fly Intel: After-Hours Movers 08/09/22 What You Missed On Wall Street On Tuesday 08/09/22 What You Missed On Wall Street This Morning APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 Applovin options imply 8.4% move in share price post-earnings 08/10/22 Largest borrow rate increases among liquid names 08/02/22 Largest borrow rate increases among liquid names 05/24/22 Applovin call volume above normal and directionally bullish U Unity $54.30 / -1.21 (-2.18%) 07/25/22 Unity Software put volume heavy and directionally bearish 07/12/22 Unity Software put volume heavy and directionally bearish 07/08/22 Unity Software call volume above normal and directionally bullish 06/16/22 Unity Software call volume above normal and directionally bullish
Hot Stocks	Terns Pharmaceuticals announces $65M oversubscribed offering » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) Terns Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 06/01/22 Terns Pharmaceuticals appoints Kerry Russell as chief medical officer 05/16/22 Terns Pharmaceuticals expects cash to fund operations into 2025 03/21/22 Terns Pharmaceuticals announces Part 1 of AVIATION trial met primary endpoint TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan 03/23/22 JPMorgan Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan 09/14/21 Goldman Sachs Terns Pharmaceuticals assumed with a Buy at Goldman Sachs TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 05/16/22 Terns Pharmaceuticals reports Q1 EPS (55c), consensus (64c) 03/03/22 Terns Pharmaceuticals reports Q4 EPS (56c), consensus (63c) TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 What You Missed On Wall Street On Wednesday 03/23/22 What You Missed On Wall Street This Morning 03/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Vontier appoints Anshooman Aga as CFO » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 VNT Vontier $24.16 / -0.315 (-1.29%) , HSC Harsco $6.56 / +0.04 (+0.61%) Vontier (VNT) announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/28/22 Vontier names Hani Joakim as Chief Technology Officer 07/19/22 Watts Water names Andre Dhawa Chief Operating Officer 02/22/22 Vontier announces $250M accelerated share repurchase agreement HSC Harsco $6.56 / +0.04 (+0.61%) 06:17 Today Harsco CFO Anshooman Aga stepping down, Pete Minan named Interim CFO 07/28/22 Clean Earth opens new 10-day hazardous waste transfer facility in Puerto Rico 07/15/22 Harsco falls -18.9% 07/15/22 Harsco falls -17.1% VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/08/22 Barclays Vontier price target lowered to $33 from $39 at Barclays 04/04/22 Barclays Vontier price target lowered to $40 from $42 at Barclays 03/23/22 Argus Vontier price target lowered to $30 from $40 at Argus 02/18/22 Citi Vontier price target lowered to $34 from $39 at Citi HSC Harsco $6.56 / +0.04 (+0.61%) 07/20/22 DA Davidson Harsco price target lowered to $13 from $16 at DA Davidson 07/18/22 Barrington Harsco price target lowered to $13 from $20 at Barrington 07/12/22 BMO Capital Harsco initiated with a Market Perform at BMO Capital 05/04/22 Barrington Harsco price target lowered to $20 from $22 at Barrington VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 08/04/22 Vontier sees 2022 revenue $80M, consensus $3.19B 08/04/22 Vontier sees FY22 adjusted EPS $3.20-$3.30, consensus $3.24 08/04/22 Vontier sees Q3 adjusted EPS 85c-90c, consensus 91c 08/04/22 Vontier reports Q2 adjusted EPS 72c, consensus 70c HSC Harsco $6.56 / +0.04 (+0.61%) 08/02/22 Harsco lowers 2022 adjusted EPS view 0c-(13c) from 35c-45c, consensus 10c 08/02/22 Harsco sees Q3 adjusted EPS (2c)-(8c), consensus 6c 08/02/22 Harsco reports Q2 adjusted EPS 1c, consensus (1c) 07/15/22 Harsco sees FY22 GAAP operating loss of ($61M)-($51M) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6
Earnings	Checkpoint Therapeutics reports Q2 EPS (16c), consensus (17c) » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 06/16/22 Checkpoint Therapeutics announces interim results from trial on cosibelimab 05/13/22 Checkpoint Therapeutics receives PIP waivers for cosibelimab from EMA CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 07/14/22 B. Riley Checkpoint Therapeutics resumed with a Buy at B. Riley 06/17/22 Lake Street Checkpoint cosibelimab data 'competitive,' says Lake Street 06/07/22 Lake Street Lake Street says Checkpoint warrants interest after cosibelimab 'shines' at ASCO 05/31/22 Cantor Fitzgerald Cantor sees 'positive' data likely coming from Checkpoint Therapeutics in June CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 05/12/22 Checkpoint Therapeutics reports Q1 EPS (20c), consensus (14c) 03/28/22 Checkpoint Therapeutics reports 2021 EPS (75c), consensus (51c) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 09/29/22 7th Annual Healthcare Conference CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 03/22/22 Checkpoint Therapeutics options imply 10.8% move in share price post-earnings 03/18/22 Checkpoint Therapeutics options imply 17.5% move in share price post-earnings 03/16/22 Checkpoint Therapeutics options imply 20.6% move in share price post-earnings
Hot Stocks	Longeveron expects cash to cover requirements into 1H24 » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 LGVN Longeveron $5.96 / -0.17 (-2.77%) Cash and short-term… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 08:03 Today Longeveron reports Q2 EPS (27c), consensus (23c) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN
Downgrade	ResMed downgraded to Neutral at Citi on valuation » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 RMD ResMed $241.21 / -2.37 (-0.97%) Citi analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed increases quarterly dividend 5% to 44c per share 08/02/22 ResMed acquires mementor, terms undisclosed 07/25/22 Philips sees completion of Respironics field action by first quarter of 2023 07/25/22 Berkeley Lights appoints Mehul Joshi as CFO RMD ResMed $241.21 / -2.37 (-0.97%) 06:33 Today RBC Capital ResMed downgraded to Sector Perform at RBC Capital on valuation 06:18 Today RBC Capital ResMed downgraded to Sector Perform from Outperform at RBC Capital 06:18 Today Citi ResMed downgraded to Neutral from Buy at Citi 06/06/22 RBC Capital ResMed upgraded to Outperform from Sector Perform at RBC Capital RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed reports Q4 EPS $1.49, consensus $1.34 04/28/22 ResMed reports Q3 EPS $1.32, consensus $1.42 RMD ResMed $241.21 / -2.37 (-0.97%) 03/24/22 Early notable gainers among liquid option names on March 24th
Earnings	VYNE Therapeutics reports Q2 adjusted EPS (13c) vs (35c) last year » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 VYNE VYNE Therapeutics / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VYNE VYNE Therapeutics / + 08/10/22 VYNE announces Phase 2a trial of FMX144 did not meet primary endpoint 06/17/22 VYNE Therapeutics completes enrollment in Phase 2a trial of FMX114 05/10/22 VYNE Therapeutics hosting KOL even on InhiBET BET Inhibitor Platform 04/07/22 VYNE Therapeutics announces Phase 1b efficacy data for FMX114 VYNE VYNE Therapeutics / + 08/10/22 H.C. Wainwright VYNE Therapeutics price target lowered to $1.50 from $7 at H.C. Wainwright 01/13/22 Roth Capital Roth raises Journey Medical target to $17 after dermatology assets acquisition 12/06/21 H.C. Wainwright VYNE Therapeutics assumed with a Buy at H.C. Wainwright 08/13/21 Northland VYNE Therapeutics price target lowered to $6 from $12 at Northland VYNE VYNE Therapeutics / + 05/12/22 VYNE Therapeutics reports adjusted Q1 EPS (14c) vs (18c) last year 03/17/22 VYNE Therapeutics reports Q4 adjusted EPS (20c) vs (43c) last year
Earnings	Longeveron reports Q2 EPS (27c), consensus (23c) » 08:03 08/12/22 08/12 08:03 08/12/22 08:03 LGVN Longeveron $5.96 / -0.17 (-2.77%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN

Recommendations	Oppenheimer says Leafly valuation 'beginning to look attractive' » 08:02 08/12/22 08/12 08:02 08/12/22 08:02 LFLY Leafly $2.25 / -0.15 (-6.25%) Oppenheimer analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LFLY Leafly $2.25 / -0.15 (-6.25%) 06/24/22 Leafly set to join Russell 3000, Russell 200 Indexes 04/14/22 Leafly names Deidre Boulware Chief People Officer 03/24/22 Leafly Holdings trading resumes 03/24/22 Leafly Holdings trading halted, volatility trading pause LFLY Leafly $2.25 / -0.15 (-6.25%) 07:32 Today Cowen Leafly price target lowered to $4 from $12 at Cowen 06:12 Today Benchmark Leafly price target lowered to $6.50 from $12.00 at Benchmark 05/20/22 Cowen Cowen starts Leafly with Outperform with its early mover advantage 05/20/22 Cowen Leafly initiated with an Outperform at Cowen LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly sees FY22 revenue $48M-$51M, three estimates $53.55M 08/11/22 Leafly reports Q2 EPS 37c, two estimates (12c) LFLY Leafly $2.25 / -0.15 (-6.25%) 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 Leafly LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly Holdings options imply 15.4% move in share price post-earnings 08/02/22 Leafly Holdings put volume heavy and directionally bearish 05/23/22 Largest borrow rate increases among liquid names 03/29/22 Leafly Holdings options imply 7.5% move in share price post-earnings
Earnings	Crinetics reports Q2 EPS (81c), consensus (67c) » 08:02 08/12/22 08/12 08:02 08/12/22 08:02 CRNX Crinetics $20.58 / -1.12 (-5.16%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly CRNX Crinetics $20.58 / -1.12 (-5.16%) 08/04/22 Crinetics to present analyses of CRN04894 preclinical, Phase 1 results 05/25/22 Crinetics reports results from Phase 1 study of CRN04894 05/12/22 Crinetics expects cash to fund operations into second half of 2024 03/30/22 Crinetics announces results from MAD cohorts of CRN04777 study CRNX Crinetics $20.58 / -1.12 (-5.16%) 06/15/22 Evercore ISI Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI 11/30/21 JMP Securities Crinetics initiated with an Outperform at JMP Securities 11/23/21 Evercore ISI Evercore starts 'rare endo treasure trove' Crinetics at Outperform 11/23/21 Evercore ISI Crinetics initiated with an Outperform at Evercore ISI CRNX Crinetics $20.58 / -1.12 (-5.16%) 05/12/22 Crinetics reports Q1 EPS (73c), consensus (58c) 03/30/22 Crinetics reports Q4 EPS (68c), consensus (62c) 13 Apr 21 Oct CRNX Crinetics $20.58 / -1.12 (-5.16%) 07/18/22 Fly Insider: Stitch Fix, Arcutis Bio among week's notable insider trades
Earnings	PepGen reports Q2 EPS ($1.23) vs ($6.03) last year » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 PEPG PepGen $11.15 / -0.27 (-2.36%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PEPG PepGen $11.15 / -0.27 (-2.36%) 07/22/22 PepGen appoints Caroline Godfrey to Scientific Advisory Board 06/16/22 PepGen expects cash to be sufficient for expenses into 1H25 06/16/22 PepGen announces anticipated upcoming milestones PEPG PepGen $11.15 / -0.27 (-2.36%) 05/31/22 Wedbush PepGen initiated with an Outperform at Wedbush 05/31/22 Stifel PepGen initiated with a Buy at Stifel 05/31/22 SVB Leerink PepGen initiated with an Outperform at SVB Leerink 05/31/22 BofA PepGen initiated with a Buy at BofA PEPG PepGen $11.15 / -0.27 (-2.36%) 06/16/22 PepGen reports Q1 EPS (18.94) vs. ($7.42) last year 06 May PEPG PepGen $11.15 / -0.27 (-2.36%) 05/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/07/22 Opening Day: Bausch + Lomb pops in public debut 08/15/22 2022 Biotech Summer Summit
Recommendations	System1 price target lowered to $19 from $26 at DA Davidson » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 SST System1 $8.69 / +0.045 (+0.52%) DA Davidson analyst Tom… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options SST System1 $8.69 / +0.045 (+0.52%) 06/07/22 System1 set to join Russell 2000, Russell 3000 Indexes 05/13/22 Starboard takes stake in Humana, exits System1 04/19/22 System1 falls -33.8% 04/19/22 System1 falls -28.6% SST System1 $8.69 / +0.045 (+0.52%) 07:06 Today Benchmark System1 price target lowered to $13 from $15 at Benchmark 07/11/22 BofA BofA starts System1 at Buy with $12 price target 07/11/22 BofA System1 initiated with a Buy at BofA 04/26/22 Evercore ISI System1 initiated with an In Line at Evercore ISI SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 sees FY22 revenue $900M-$930M, consensus $997.34M 08/11/22 System1 reports Q2 revenue $220M, consensus $218.82M 04/04/22 System1 sees FY22 revenue $1B 04/04/22 System1 reports Q4 revenue $238.9M vs. $160.9M last year SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 Fly Intel: After-Hours Movers 05/20/22 Proven algorithm says sell these stocks now 04/19/22 What You Missed On Wall Street This Morning 04/18/22 Fly Intel: After-Hours Movers 09/08/22 Consumer/Media/Entertainment Conference SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 options imply 10.1% move in share price post-earnings 07/29/22 Largest borrow rate increases among liquid names 07/22/22 Largest borrow rate increases among liquid names 07/21/22 Largest borrow rate increases among liquid names
Earnings	BIO-key sees 2022 revenue $10M-$13M » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 BKYI BIO-key $2.15 / +0.115 (+5.65%) "BIO-key has built a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings Events BKYI BIO-key $2.15 / +0.115 (+5.65%) 07/21/22 Long Island University selects BIO-key's PortalGuard IAM platform 07/18/22 Darksteel Technologies selects PortalGuard IAM 07/14/22 BIO-key to showcase PortalGuard IAM at NACo Annual Conference 06/21/22 BIO-key showcases biometric cybersecurity solutions at MSP Expo Florida BKYI BIO-key $2.15 / +0.115 (+5.65%) 08:00 Today BIO-key reports Q2 EP (21c) vs. (15c) last year 05/16/22 BIO-key sees 2022 revenue $10M-$13M 05/16/22 BIO-key reports Q1 EPS (12c) vs. (11c) last year 03/29/22 BIO-key sees 2022 revenue $10M-$13M, one est. $15M 10:00 Today BIO-key - BKYI
Downgrade	Wrap Technologies downgraded to Neutral from Buy at Ladenburg » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 WRAP Wrap Technologies $2.07 / +0.22 (+11.89%) Ladenburg analyst Jon… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings WRAP Wrap Technologies $2.07 / +0.22 (+11.89%) 08/10/22 Wrap Technologies expects increased sales momentum in back half of FY22 07/29/22 Wrap Technologies announces deployment of BolaWrap device in Oregon 07/25/22 Wrap Technologies appoints DeAlmeida as CFO 07/21/22 Wrap Technologies announces sale of Societal Reentry VR Enterprise Platform WRAP Wrap Technologies $2.07 / +0.22 (+11.89%) 03/11/22 Ladenburg Wrap Technologies price target lowered to $5.25 from $6.25 at Ladenburg 01/25/22 Maxim Wrap Technologies downgraded to Hold at Maxim on management departures 01/25/22 Maxim Wrap Technologies downgraded to Hold from Buy at Maxim 01/03/22 Ladenburg Ladenburg uncovers 'significant loss' of future sales for Wrap Technologies WRAP Wrap Technologies $2.07 / +0.22 (+11.89%) 08/10/22 Wrap Technologies reports Q2 EPS (12c), consensus (13c) 05/03/22 Wrap Technologies reports Q1 EPS (13c), consensus (12c) 05/03/22 Wrap Technologies reports Q1 EPS (13c), consensus (12c) 05/03/22 Wrap Technologies reports Q1 EPS (13c), consensus (12c)
Earnings	BIO-key reports Q2 EP (21c) vs. (15c) last year » 08:00 08/12/22 08/12 08:00 08/12/22 08:00 BKYI BIO-key $2.15 / +0.115 (+5.65%) Reports Q2 revenue $1.9M … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings Events BKYI BIO-key $2.15 / +0.115 (+5.65%) 07/21/22 Long Island University selects BIO-key's PortalGuard IAM platform 07/18/22 Darksteel Technologies selects PortalGuard IAM 07/14/22 BIO-key to showcase PortalGuard IAM at NACo Annual Conference 06/21/22 BIO-key showcases biometric cybersecurity solutions at MSP Expo Florida BKYI BIO-key $2.15 / +0.115 (+5.65%) 05/16/22 BIO-key sees 2022 revenue $10M-$13M 05/16/22 BIO-key reports Q1 EPS (12c) vs. (11c) last year 03/29/22 BIO-key sees 2022 revenue $10M-$13M, one est. $15M 03/29/22 BIO-key reports Q4 EPS (26c) vs. (18c) last year 10:00 Today BIO-key - BKYI
Options	Apple put buyer realizes 14% same-day gains » 08:00 08/12/22 08/12 08:00 08/12/22 08:00 AAPL Apple $168.49 / -0.73 (-0.43%) Notable profits for the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options AAPL Apple $168.49 / -0.73 (-0.43%) 08/03/22 Microsoft says Teams now optimized for Mac computers 07/28/22 Apple says 'constantly surveilling' the market for potential acquisitions 07/28/22 Apple expects Q4 revenue to accelerate y/y 07/28/22 Apple says response to iPhone 13 'continues to be strong' AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Craig-Hallum Enovix price target raised to $25 from $20 at Craig-Hallum 08/11/22 Loop Capital Loop Capital has 'stronger conviction' in Enovix after 'customer milestones' 08/10/22 Bernstein Apple Services performance fundamentally better than believed, says Bernstein 08/08/22 B. Riley B. Riley thinks Globalstar's mystery satellite capacity customer is Apple AAPL Apple $168.49 / -0.73 (-0.43%) 07/28/22 Apple reports Q3 EPS $1.20, consensus $1.16 07/28/22 Notable companies reporting after market close 04/28/22 Apple says y/y Q3 revenue growth to be impacted by COVID 04/28/22 Apple reports Q2 EPS $1.52, consensus $1.43 AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Apple assemblers seen making 220M iPhones for 2022, Bloomberg says 08/10/22 Apple signs agreement with 'Suave' maker Futuro Studios, Bloomberg reports 08/10/22 TSMC receives sub-7nm chip orders from Qualcomm, DigiTimes reports 08/10/22 Taiwan wants Foxconn to unwind stake in Tsinghua, FT reports AAPL Apple $168.49 / -0.73 (-0.43%) 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter 08/10/22 What Wall Street is saying about Disney ahead of earnings 08/09/22 What You Missed On Wall Street This Morning 08/08/22 What You Missed On Wall Street This Morning AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Notable open interest changes for August 11th 08/10/22 Notable open interest changes for August 10th 08/09/22 Notable open interest changes for August 9th 08/08/22 Notable open interest changes for August 8th
Recommendations	Roblox price target raised to $52 from $45 at Deutsche Bank » 07:56 08/12/22 08/12 07:56 08/12/22 07:56 RBLX Roblox $49.55 / +1.52 (+3.16%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 Cathie Wood's ARK Investment bought 191K shares of Roblox today 08/09/22 Roblox drops 13% to $41.29 after Q2 results miss estimates 08/09/22 Roblox reports Q2 bookings $639.9M, down 4% y/y 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD RBLX Roblox $49.55 / +1.52 (+3.16%) 08/11/22 Wedbush Roblox price target raised to $34 from $28 at Wedbush 08/10/22 Morgan Stanley Roblox price target raised to $32 from $25 at Morgan Stanley 08/08/22 Truist Roblox price target raised to $45 from $29 at Truist 08/01/22 MKM Partners Roblox price target raised to $40 from $28 at MKM Partners RBLX Roblox $49.55 / +1.52 (+3.16%) 08/09/22 Roblox reports Q2 EPS (30c), consensus (23c) 08/09/22 Notable companies reporting after market close 05/10/22 Roblox reports Q1 EPS (27c), consensus (21c) 05/10/22 Notable companies reporting after market close RBLX Roblox $49.55 / +1.52 (+3.16%) 04/06/22 Meta plans to introduce virtual coins for the metaverse, FT reports RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 08/10/22 Fly Intel: Pre-market Movers 08/09/22 Fly Intel: After-Hours Movers RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 Roblox put buyer realizes 18% same-day gains 08/09/22 Roblox options imply 15.6% move in share price post-earnings 07/08/22 Unusually active option classes on open July 8th 07/06/22 Unusually active option classes on open July 6th
Recommendations	Oppenheimer encouraged as 'key initiatives taking hold' at CarMax » 07:56 08/12/22 08/12 07:56 08/12/22 07:56 KMX CarMax $101.64 / +1.71 (+1.71%) Oppenheimer analyst Brian… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 CarMax plans to open ten new locations in FY23 06/24/22 CarMax sold 427,257 units in Q1, down 5.5% from the prior year quarter 05/16/22 Tepper's Appaloosa buys two casinos in Q1, exits T-Mobile and GM 04/12/22 CarMax drops 5% to $98.05 after Q4 earnings miss estimates KMX CarMax $101.64 / +1.71 (+1.71%) 07/14/22 Morgan Stanley CarMax price target lowered to $124 from $140 at Morgan Stanley 06/27/22 RBC Capital CarMax price target raised to $108 from $104 at RBC Capital 06/27/22 Wedbush CarMax price target raised to $105 from $90 at Wedbush 06/27/22 Baird CarMax valuation attractive for patient investors, says Baird KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 CarMax reports Q1 EPS $1.56, consensus $1.49 06/23/22 Notable companies reporting before tomorrow's open 06/23/22 Notable companies reporting before tomorrow's open 04/12/22 CarMax reports Q4 EPS 98c, consensus $1.25 KMX CarMax $101.64 / +1.71 (+1.71%) 02/26/22 Deere among quality companies doing business mostly in the U.S., Barron's says KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 What You Missed On Wall Street On Friday 06/24/22 What You Missed On Wall Street This Morning 05/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/22 What You Missed On Wall Street On Wednesday 09/29/22 CarMax - KMX KMX CarMax $101.64 / +1.71 (+1.71%) 04/12/22 Unusually active option classes on open April 12th

Recommendations	GeoPark price target lowered to $22 from $24 at Canaccord » 07:54 08/12/22 08/12 07:54 08/12/22 07:54 GPRK GeoPark $12.50 / +0.55 (+4.60%) Canaccord lowered the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings GPRK GeoPark $12.50 / +0.55 (+4.60%) 08/10/22 GeoPark raises quarterly dividend by 50% to 12.7c per share 06/21/22 GeoPark provides business activity update 06/21/22 GeoPark falls -8.9% 06/21/22 GeoPark falls -7.4% GPRK GeoPark $12.50 / +0.55 (+4.60%) 03/09/22 GeoPark reports Q4 adjusted EBITDA $87.1M vs. $56.0M last year
Recommendations	ForgeRock price target raised to $20 from $15 at Deutsche Bank » 07:54 08/12/22 08/12 07:54 08/12/22 07:54 FORG ForgeRock $22.24 / -1.13 (-4.84%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock reports Q2 ARR $201.6M, up 30% y/y 05/11/22 ForgeRock introduces ForgeRock Autonomous Access 03/02/22 ForgeRock falls -10.0% FORG ForgeRock $22.24 / -1.13 (-4.84%) 07:39 Today Cowen ForgeRock price target lowered to $25 from $28 at Cowen 07/13/22 Piper Sandler ForgeRock price target raised to $25 from $24 at Piper Sandler 06/22/22 JPMorgan ForgeRock price target lowered to $30 from $36 at JPMorgan 05/12/22 Deutsche Bank ForgeRock price target lowered to $15 from $16 at Deutsche Bank FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock sees FY22 adjusted EPS (49c)-(44c), consensus (42c) 08/11/22 ForgeRock sees Q3 adjusted EPS (17c)-(13c), consensus (7c) 08/11/22 ForgeRock reports Q2 adjusted EPS (17c), consensus (21c) 05/11/22 ForgeRock cuts FY22 EPS view to (45c)-(41c) from (38c)-(34c), consensus (36c) 16 Sep FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 Fly Intel: After-Hours Movers 02/26/22 Short Report: Avis Budget, VTEX short interest at multi-week highs 08/23/22 ForgeRock 08/28/22 ForgeRock
Recommendations	Privia Health price target raised to $51 from $36 at Guggenheim » 07:53 08/12/22 08/12 07:53 08/12/22 07:53 PRVA Privia Health $37.81 / +1.42 (+3.90%) Guggenheim analyst Sandy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PRVA Privia Health $37.81 / +1.42 (+3.90%) 03/31/22 Privia Health appoints Cocozza to board of directors 03/22/22 Privia Health CFO Jeff Sherman resigns PRVA Privia Health $37.81 / +1.42 (+3.90%) 07:49 Today Canaccord Privia Health price target raised to $45 from $40 at Canaccord 07:41 Today Cowen Privia Health price target raised to $44 from $35 at Cowen 07/14/22 Truist Privia Health price target raised to $40 from $36 at Truist 06/29/22 Canaccord Privia Health price target raised to $40 from $29 at Canaccord PRVA Privia Health $37.81 / +1.42 (+3.90%) 08/11/22 Privia Health sees 2022 revenue at high end of $1.225B-$1.3B 08/11/22 Privia Health reports Q2 adjusted EPS 13c vs. 9c last year. 05/12/22 Privia Health sees FY22 revenue at the mid to high end of $1.225B-$1.3B range 05/12/22 Privia Health reports Q1 adjusted EPS 12c, consensus (4c) 19 Nov PRVA Privia Health $37.81 / +1.42 (+3.90%) 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/20/22 Privia Health 09/21/22 Privia Health
Recommendations	2seventy Bio price target lowered to $28 from $42 at Canaccord » 07:51 08/12/22 08/12 07:51 08/12/22 07:51 TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) Canaccord analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 08/10/22 Bristol-Myers, 2seventy Bio: KarMMa-3 trial met primary endpoint 05/12/22 2seventy Bio sees $250M-$300M total U.S. commercial revenue in 2022 02/14/22 2seventy Bio appoints Steven Bernstein as CMO TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 05/02/22 Goldman Sachs 2seventy Bio initiated with a Buy at Goldman Sachs 02/10/22 SVB Leerink SVB Leerink bullish on 2seventy Bio, initiates with an Outperform 02/10/22 SVB Leerink 2seventy Bio initiated with an Outperform at SVB Leerink TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 08/10/22 2seventy Bio reports Q2 EPS ($2.02), consensus ($2.08) 05/12/22 2seventy Bio reports Q1 EPS ($3.20), consensus ($2.05) 03/22/22 2seventy Bio reports Q4 EPS ($2.55), consensus ($2.84) TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 07/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 04/29/22 Fourteen new option listings and one option delisting on April 29th
Recommendations	Karuna Therapeutics price target raised to $330 from $200 at Guggenheim » 07:51 08/12/22 08/12 07:51 08/12/22 07:51 KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) Guggenheim analyst Yatin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 Zai Lab partner Karuna announces results from Phase 3 EMERGENT-2 trial 08/08/22 Karuna Therapeutics says Phase 3 EMERGENT-2 trial met primary endpoint KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/10/22 Wells Fargo Karuna Therapeutics price target raised to $264 from $186 at Wells Fargo 08/09/22 Mizuho Karuna Therapeutics price target raised to $276 from $190 at Mizuho 08/09/22 Citi Zai Lab price target raised to $199 from $193 at Citi 08/09/22 BofA Karuna Therapeutics price target raised to $261 from $160 at BofA KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 Karuna Therapeutics reports Q2 EPS ($2.17), consensus ($2.09) 05/05/22 Karuna Therapeutics reports Q1 EPS ($1.95), consensus ($2.11) 02/24/22 Karuna Therapeutics reports Q4 EPS (94c), consensus ($1.73) 10 Aug 10 Nov KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 07/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/15/22 2022 Biotech Summer Summit

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event
PLXP
Today at 08:30

PLx Pharma - PLXP Conference Calls
RPID
Today at 08:30

Rapid Micro Biosystems - RPID Conference Calls
FLO
Today at 08:30

Flowers Foods - FLO Conference Calls
HOFV
Today at 08:30

Hall of Fame Resort & Entertainment - HOFV Conference Calls
KINS
Today at 08:30

Kingstone Companies - KINS Conference Calls
RGF
Today at 08:30

Real Good Food - RGF Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

HTG Molecular releases whitepaper for transcriptome-informed approach

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access